257 results on '"Acharya, Suchitra"'
Search Results
2. Exploration of rotational thromboelastometry (ROTEM) to characterize the coagulation profiles of newly diagnosed pediatric leukemia patients
3. Rare Coagulation Factor Deficiencies
4. Disorders of coagulation
5. List of contributors
6. Pediatric Bleeding Questionnaire as a predictor of perioperative bleeding in patients with low factor VII levels
7. Retrospective chart review of GI bleeding in people with von Willebrand disease.
8. Prolonged Prothrombin Time Does Not Correlate with Clinical Bleeding Symptoms in Newly Diagnosed Pediatric Leukemia Patients
9. Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial
10. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
11. Evaluation of the Safety and Efficacy of Enoxaparin Once-Daily Versus Twice-Daily Dosing for Prophylaxis in Pediatric Patients.
12. HTRS2023.O8C.2 Eptacog beta efficacy and safety in underweight, normal weight, and overweight/obese persons with hemophilia A or B and inhibitors
13. Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway
14. Bleeding Risks With Vitamin K Deficiency
15. Bleeding Risks With Renal Disease
16. List of Contributors
17. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders
18. Prolonged prothrombin time does not correlate with clinical bleeding symptoms in newly diagnosed paediatric leukaemia patients
19. Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
20. Quality of life in a large multinational haemophilia B cohort (The B-Natural study) – Unmet needs remain
21. Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children
22. Quality of life in a large multinational haemophilia B cohort (The B‐Natural study) – Unmet needs remain
23. List of Contributors
24. Disorders of Coagulation
25. Neoangiogenesis contributes to the development of hemophilic synovitis
26. Multisystem inflammatory syndrome in children (MIS‐C) and the prothrombotic state: Coagulation profiles and rotational thromboelastometry in a MIS‐C cohort
27. Six Month Follow-up of Patients With Multi-System Inflammatory Syndrome in Children
28. Perceptions about the efficacy of extended half‐life (EHL) factor products in persons with haemophilia (PWH): A national survey of haemophilia providers from haemophilia treatment centres (HTCs) in the United States
29. Primary thromboprophylaxis to prevent thrombotic events in pediatric oncology patients with a malignant mediastinal mass
30. Risk Factors for Joint Bleeding in Severe Hemophilia a and B: Analysis of the Community Counts Longitudinal Surveillance Cohort
31. The homozygous VHLD126N missense mutation is associated with dramatically elevated erythropoietin levels, consequent polycythemia, and early onset severe pulmonary hypertension
32. The B‐Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
33. Varying Psychological Impacts of COVID-19 and Functional/Dysfunctional Coping Strategies: A Mixed-Method Approach
34. DOCK8 mutations in COVID-19 and MIS-C Cytokine Storm Syndrome
35. The B-Natural study—The outcome of immune tolerance induction therapy in patients with severe haemophilia B
36. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural)
37. Hemophilic joint disease – current perspective and potential future strategies
38. Primary Thromboprophylaxis to Prevent Thrombotic Events in Pediatric Oncology Patients with a Malignant Mediastinal Mass.
39. Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia
40. Assessment of provider practices regarding venous thromboembolism management and prevention in pediatric acute leukemia patients
41. Effect of COVID‐19 on anakinra‐induced remission in homozygous STX11 hemophagocytosis lymphohistiocytosis
42. Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID‐19 infection
43. Neonate born with ischemic limb to a COVID-19 positive mother: management and review of literature
44. Natural history study of factor IX deficiency with focus on treatment and complications (B‐Natural)
45. Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices
46. Retrospective Chart Review of Gastrointestinal Bleeding in Patients with Von Willebrand Disease
47. Real-World Experience Using Emicizumab Prophylaxis for Hemophilia a: Single-Center Experience
48. Contributors
49. Management of factor VIII inhibitors
50. Exploration of the pathogenesis of haemophilic joint arthropathy: understanding implications for optimal clinical management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.